Working towards a better understanding of VEXAS syndrome
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20949
Abstract: cal mast-cell stabilizers, topical corticosteroids and topical calcineurin inhibitors. Dose adjustment or even cessation of the causative drug may be required in severe cases. In conclusion, with the limited data, it appears that tralokinumab is… read more here.
Keywords: better understanding; ophthalmology; towards better; understanding vexas ... See more keywords